This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_MELANOMA_EAR_EXALLC for full statistics.
Melanoma in situ of ear and external auricular canal
CD2_INSITU_MELANOMA_EAR
melanoma: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
32 |
4. Check minimum number of eventsNone |
32 |
5. Include endpointsNone |
32 |
6. Filter based on genotype QC (FinnGen only) |
32 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D03
- Name in latin
- Melanoma in situ auriculae
Similar endpoints
↥List of similar endpoints to
Melanoma in situ of ear and external auricular canal
based on the number of shared cases.
Similar with more cases:
- Melanoma in situ of ear and external auricular canal
- Melanoma in situ
- Melanoma in situ
- Malignant melanoma
- Malignant melanoma, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 32 | 15 | 17 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 70.36 | 67.31 | 73.04 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3002256) Pathology report gross observation
20
26
18.85
16.45
1.5
1.3
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
25
106
7.17
5.97
4.2
2.2
—
—
—
0
0
(40768443) Skin Pathology biopsy report
8
8
12.79
4.82
1.0
1.5
—
—
—
0
0
(3033658) Prothrombin time (PT) actual/Normal
16
62
4.16
3.76
2.3
3.9
%
71.0
84.3
1.09
16
62
(4035726)
10
27
4.93
3.68
1.5
1.2
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
18
85
3.55
3.04
5.6
6.0
—
—
—
0
0
(3022096) Basophils/100 leukocytes in Blood
21
111
3.59
2.95
6.1
6.6
%
0.7
0.6
0.51
21
104
(3019069) Monocytes/100 leukocytes in Blood
21
114
3.45
2.77
6.1
7.0
%
9.4
8.5
0.71
21
108
(3018010) Neutrophils/100 leukocytes in Blood
21
118
3.27
2.54
6.4
6.5
%
58.1
58.2
0.01
21
113
(3022145) Colonoscopy Study observation
9
32
3.50
2.21
1.3
1.3
—
—
—
0
0
(3019198) Lymphocytes [#/volume] in Blood
21
131
2.75
1.91
6.4
6.0
e9/l
1.7
1.8
0.26
15
115
(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
32
276
+∞
1.67
10.3
11.6
u/l
22.9
23.8
0.13
32
266
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
6
20
3.44
1.67
1.3
1.6
—
—
—
0
0
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
5
16
3.50
1.50
11.2
10.5
—
—
—
0
0
(3019225) pH of Specimen
6
26
2.60
1.25
3.7
4.2
—
—
—
0
0
(3000963) Hemoglobin [Mass/volume] in Blood
32
285
+∞
1.24
21.2
26.3
g/l
135.9
133.1
0.52
32
280
(3035941) MCH [Entitic mass]
32
285
+∞
1.24
20.7
26.0
pg
30.6
30.5
0.18
32
280
(3024731) MCV [Entitic volume]
32
285
+∞
1.24
21.1
26.0
fl
91.9
91.8
0.06
32
280
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
6
112
0.43
1.11
2.2
4.0
—
—
—
0
0
(3014007) Fractional oxyhemoglobin in Arterial blood
5
22
2.50
1.07
13.0
11.9
%
92.0
91.0
—
5
22
(3019060) Gas panel - Arterial blood
0
32
0.00
1.01
0.0
3.0
—
—
—
0
0
(3000494) Fungus identified in Specimen by Culture
6
29
2.31
0.95
1.3
1.7
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
17
121
1.86
0.88
1.9
2.3
—
—
—
0
0
(3027273) Bicarbonate [Moles/volume] in Venous blood
0
25
0.00
0.83
0.0
2.6
—
24.2
—
0
25
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
0
27
0.00
0.81
0.0
2.9
—
48.9
—
0
27
(3006217) Methemoglobin/Hemoglobin.total in Arterial blood
5
23
2.38
0.80
12.2
11.2
%
0.4
0.7
—
5
23
(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood
5
24
2.28
0.78
13.0
11.0
%
1.3
1.9
—
5
24
(3000991) Gas panel - Venous blood
5
25
2.18
0.76
13.4
11.7
—
—
—
0
0
(3021589) Normoblasts [#/volume] in Blood
17
127
1.72
0.70
10.6
13.0
e9/l
0.0
0.0
0.50
12
107
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
16
121
1.64
0.61
2.2
2.2
pmol/l
126.0
88.8
—
7
69
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
27
240
1.80
0.55
3.6
4.4
mmol/l
1.0
1.2
2.64
27
215
(3023368) Bacteria identified in Blood by Culture
6
91
0.58
0.52
4.8
4.7
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
24
208
1.61
0.48
23.0
21.1
%
41.1
37.8
1.60
19
126
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
10
72
1.57
0.43
1.4
2.0
—
—
—
0
0
(36660697) Celiac disease serology panel - Serum
0
15
0.00
0.42
0.0
1.2
—
—
—
0
0
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
0
15
0.00
0.42
0.0
1.3
—
—
—
0
0
(3008037) Lactate [Moles/volume] in Venous blood
0
16
0.00
0.42
0.0
2.8
—
1.5
—
0
16
(3038515) Glucose [Moles/volume] in Venous blood
0
16
0.00
0.42
0.0
2.8
—
8.0
—
0
16
(1761482) Bacteria [#/volume] in Urine by Culture
0
16
0.00
0.42
0.0
5.3
—
—
—
0
0
(3020891) Body temperature
0
17
0.00
0.42
0.0
3.6
—
—
—
0
0
(3018405) Lactate [Moles/volume] in Arterial blood
0
17
0.00
0.42
0.0
6.6
—
1.4
—
0
17
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
0
18
0.00
0.41
0.0
1.4
—
—
—
0
0
(3013512) EKG study
13
102
1.46
0.38
3.2
4.3
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
12
93
1.46
0.37
1.5
2.1
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
7
53
1.41
0.34
1.3
2.0
—
—
—
0
0
(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma
8
64
1.33
0.31
5.6
3.4
ng/l
281.9
22.7
—
8
54
(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma
27
250
1.51
0.30
4.1
4.9
mmol/l
1.5
1.4
0.35
27
224
(3041096) Erythrocytes [Presence] in Urine by Automated
5
73
0.63
0.30
1.6
3.9
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
21
185
1.39
0.30
3.0
4.6
—
—
—
0
0
(40758558) Short blood count panel - Blood
9
73
1.32
0.29
4.4
7.5
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
8
99
0.74
0.26
1.9
3.3
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
9
112
0.73
0.25
2.1
3.2
—
—
—
0
0
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
5
37
1.41
0.25
1.4
2.0
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
5
38
1.37
0.24
1.4
1.9
—
—
—
0
0
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
0
11
0.00
0.22
0.0
1.4
—
—
—
0
0
(3005702) Mycobacterium sp identified in Specimen by Organism specific culture
0
11
0.00
0.22
0.0
1.3
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
0
11
0.00
0.22
0.0
1.7
—
—
—
0
0
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
10
0.00
0.22
0.0
1.1
—
—
—
0
0
(3004490) Bicarbonate [Moles/volume] standard in Capillary blood
0
10
0.00
0.22
0.0
1.5
—
24.4
—
0
10
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
12
0.00
0.21
0.0
2.2
—
—
—
0
0
(3041354) Potassium [Moles/volume] in Venous blood
0
12
0.00
0.21
0.0
2.7
—
4.1
—
0
12
(3033705) Calcium.ionized [Moles/volume] in Venous blood
0
12
0.00
0.21
0.0
2.7
—
—
—
0
0
(3035285) Chloride [Moles/volume] in Venous blood
0
12
0.00
0.21
0.0
2.7
—
106.5
—
0
12
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
(3022313) Gas panel - Capillary blood
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
(3025941) Bacteria identified in Stool by Culture
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
(4034850)
0
14
0.00
0.20
0.0
13.6
—
—
—
0
0
(3003396) Base excess in Arterial blood by calculation
5
43
1.19
0.10
13.0
9.5
mmol/l
-0.4
2.4
—
5
34
(40760892) CBC W Ordered Manual Differential panel - Blood
5
61
0.79
0.09
2.6
5.4
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
6
72
0.80
0.08
1.2
1.4
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
8
74
1.11
0.08
2.1
3.4
—
—
—
0
0
(3018095) Leukocytes [#/volume] in Urine
11
103
1.10
0.02
2.4
3.7
e6/l
5.3
61.8
—
5
76
(3013707) Erythrocyte sedimentation rate by Westergren method
20
207
0.91
0.02
3.5
5.1
mm/h
10.3
14.5
0.88
20
190
(3044889) 12 lead EKG panel
19
184
1.08
0.01
3.7
4.7
—
—
—
0
0
(3002385) Erythrocyte distribution width [Ratio]
22
216
1.06
0.00
22.6
22.5
%
13.3
13.9
2.03
22
209
(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(3037756) Immunofixation for Serum or Plasma
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3036432) Mycobacterium tuberculosis genotype [Identifier] in Isolate
0
5
0.00
0.00
0.0
10.0
—
—
—
0
0
(3020961) Endomysium IgA Ab [Titer] in Serum
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma
0
8
0.00
0.00
0.0
1.6
—
36.8
—
0
8
(1616796) Gas panel - Central venous blood
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
(3050129) First trimester maternal screen panel - Serum or Plasma
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(40762485) Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3027315) Oxygen [Partial pressure] in Blood
0
7
0.00
0.00
0.0
4.0
—
8.3
—
0
7
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3042111) Morphology [Interpretation] in Bone marrow Narrative
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
(3021788) Differential panel - Synovial fluid
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(3023419) Bacteria identified in Sputum by Culture
0
8
0.00
0.00
0.0
3.7
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
14
140
1.00
0.00
2.1
4.6
—
—
—
0
0
(3050238) Crystals [Presence] in Synovial fluid by Light microscopy
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(40768800) Prostate Pathology biopsy report
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
6
68
0.86
0.00
2.0
3.7
—
—
—
0
0
(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(3012110) Lysozyme [Mass/volume] in Serum or Plasma
0
8
0.00
0.00
0.0
2.1
—
10.4
—
0
8
(3011363) Streptococcus pneumoniae Ag [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3013290) Carbon dioxide [Partial pressure] in Blood
0
7
0.00
0.00
0.0
4.0
—
5.1
—
0
7
(3021901) Oxygen saturation in Capillary blood
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
2.7
—
15.8
—
0
6
(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3027544) Mycobacterium sp identified in Sputum by Organism specific culture
0
7
0.00
0.00
0.0
3.9
—
—
—
0
0
(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(3032836) C peptide [Moles/volume] in Serum or Plasma --fasting
0
7
0.00
0.00
0.0
1.0
—
0.9
—
0
7
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_MELANOMA_EAR – Melanoma in situ of ear and external auricular canal
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).